Rhythm Pharmaceuticals (RYTM) CSO Alastair Garfield Sells Shares

What Happened Alastair Garfield, Chief Scientific Officer of Rhythm Pharmaceuticals (RYTM), sold a total of 7,763 shares in open-market transactions on August 13, 2026, generating approximately $912,703 in gross proceeds. The sales were reported in four blocks: 2,007 shares at a weighted average $116.11 ($233,031), 1,556 shares at $117.08 ($182,170), 3,400 shares at $118.28 ($402,167), and 800 shares at $119.17 ($95,335). These were disposals (sales), which are commonly routine; they do not on their own indicate insider sentiment.

Key Details

• Transaction date: August 13, 2026 (reported on Form 4 filed Aug 17, 2026).
• Share totals/prices: 2,007 @ $116.11; 1,556 @ $117.08; 3,400 @ $118.28; 800 @ $119.17. Total shares sold = 7,763; total proceeds ≈ $912,703.
• Footnotes: Sales were made pursuant to a Rule 10b5‑1 trading plan adopted May 14, 2026 (F1). Reported prices are weighted averages with price ranges by block: $115.67–$116.62 (F2), $116.72–$117.66 (F3), $117.73–$118.71 (F4), and $118.73–$119.52 (F5). The filing offers to provide a breakdown of the per‑trade prices on request.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Timeliness: Form 4 was filed Aug 17, 2026 for trades on Aug 13, 2026 (appears to be filed within the typical two-business-day window).

Context These trades were executed under a prearranged 10b5‑1 plan, which allows insiders to sell shares according to a preset schedule and is often used to avoid trading based on material nonpublic information. For retail investors, purchases by insiders tend to be more informative than routine sales; sales under 10b5‑1 plans are common and may reflect diversification or planned liquidity rather than a view on company fundamentals.